Medicare AdvantagePrior AuthHigh impact
Imbruvica® (ibrutinib) (Revised)
Humana·Hematology, Oncology, Internal Medicine·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Aug 12, 2026
Summary
Humana has issued a revised Prior Authorization policy for Imbruvica (ibrutinib) effective January 1, 2026, with updates as of April 22, 2026. The policy covers four approved indications: CLL/SLL, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma (second-line/subsequent monotherapy only), and Chronic Graft Versus Host Disease (age 1+, after prior systemic therapy failure). All approvals require prior authorization and will be denied if the member has experienced disease progression while on or after Imbruvica. Billing teams must implement these criteria into authorization workflows immediately.
Action Required
By January 1, 2026: Billing and authorization teams must implement the following prior authorization requirements in all systems:
1. FOR ALL IMBRUVICA REQUESTS: Configure the billing system to require prior authorization before claims are processed. The policy applies to all Imbruvica formulations (70mg/140mg capsules, 140mg/280mg/420mg tablets, 70mg/mL oral suspension).
2. DIAGNOSIS-SPECIFIC CRITERIA:
- CLL/SLL cases: Verify diagnosis documentation only (Criteria #1 met = approval eligible)
- Waldenstrom's Macroglobulinemia: Verify diagnosis AND confirm monotherapy or combination with rituximab product
- Marginal Zone Lymphoma: Verify diagnosis AND confirm second-line/subsequent therapy for refractory/progressive disease AND confirm monotherapy use
- Chronic Graft Versus Host Disease: Verify diagnosis AND age ≥1 year AND document at least one prior failed systemic therapy line (e.g., corticosteroids)
3. UNIVERSAL EXCLUSION: Deny approval if member has experienced disease progression while on or following Imbruvica therapy.
4. APPROVAL DURATION: Set initial and renewal approvals for plan year duration.
5. CLINICAL ALERTS: Add system flags requiring provider acknowledgment of black box warnings (hemorrhage risk—up to 6% Grade 3+ bleeding; infection risk—14-26% Grade 3+ infections; cytopenias; atrial fibrillation 6-9%). Document that providers must monitor CBC monthly and manage arrhythmias if they develop.
6. DOCUMENTATION REQUIREMENTS: Providers submitting Imbruvica requests must submit diagnosis confirmation, prior therapy history (especially for MZL and cGVHD), and current disease status (no progression on prior Imbruvica).
7. WORKFLOW: Update all PA submission forms, EMR templates, and billing software rules to enforce these criteria before claim submission. Train front-desk staff to collect required diagnosis/history information at time of service.
FAILURE TO IMPLEMENT: Claims submitted without prior authorization or failing to meet indication-specific criteria will be denied. Retroactive denials may apply if authorization requirements are not met prospectively.